2500 — Venus MedTech HangZhou Income Statement
0.000.00%
- HK$1.07bn
- HK$1.29bn
- CNY470.83m
Annual income statement for Venus MedTech HangZhou, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 276 | 416 | 406 | 491 | 471 |
| Cost of Revenue | |||||
| Gross Profit | 227 | 324 | 314 | 389 | 368 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 458 | 780 | 1,504 | 1,152 | 1,191 |
| Operating Profit | -182 | -364 | -1,098 | -660 | -720 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -186 | -378 | -1,156 | -735 | -741 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -183 | -371 | -1,122 | -729 | -717 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -182 | -374 | -1,058 | -704 | -714 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -182 | -374 | -1,058 | -704 | -714 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.444 | -0.497 | -1.76 | -1.24 | -1.36 |